false
0001712762
0001712762
2023-11-30
2023-11-30
0001712762
BIAF:CommonStockParValue.007PerShareMember
2023-11-30
2023-11-30
0001712762
BIAF:TradeableWarrantsToPurchaseCommonStockMember
2023-11-30
2023-11-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 30, 2023
BIOAFFINITY
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41463 |
|
46-5211056 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
22211
W Interstate 10
Suite
1206
San
Antonio, Texas 78257
(210)
698-5334
(Address
of principal executive offices and Registrant’s telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $.007 per share |
|
BIAF |
|
The
Nasdaq Stock Market LLC |
Tradeable
Warrants to purchase Common Stock |
|
BIAFW |
|
The
Nasdaq Stock Market LLC |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01 Regulation FD Disclosure.
On
November 30, 2023, bioAffinity Technologies, Inc. (the “Company”) issued a press release announcing that the Centers for
Medicare and Medicaid Services (“CMS”) has made a final determination for payment for CyPath® Lung, the Company’s
noninvasive test for early-stage lung cancer, for the 2024 calendar year and that CyPath® Lung is now on CMS’ 2024 clinical
laboratory fee schedule.
Based
on the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests recommendation, in September 2023 CMS had previously released
a preliminary payment decision for the Current Procedural Terminology (“CPT”) code specific to CyPath® Lung. For the
calendar year 2024 Medicare Clinical Lab Fee Schedule, CMS has finalized the panel’s recommendation for CyPath® Lung for purposes
of payment by Medicare. This payment information also serves as a reference for private payers and other public health insurance programs.
On
November 30, 2023, the Company issued a press release disclosing the foregoing. A copy of the press release is furnished with this Current
Report on Form 8-K as Exhibit 99.1 and incorporated by reference into this Item 7.01.The
information in this Item 7.01 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed
to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this
Item 7.01 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference
into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless
of any general incorporation language in such filing.
The
press release attached as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the
Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking”
rather than historical.
The
Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it
may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports
or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.
Item
8.01. Other Events.
On
November 30, 2023, the “Company issued a press release announcing that CMS has made a final determination for payment for CyPath®
Lung, the Company’s noninvasive test for early-stage lung cancer, for the 2024 calendar year and that CyPath® Lung is now on
CMS’ 2024 clinical laboratory fee schedule.
In
March 2023, the Company applied to the American Medical Association (“AMA”) for a CPT code specific to CyPath® Lung.
At that time, Precision Pathology Services, now Precision Pathology Laboratory Services (“PPLS”), a subsidiary of the Company,
billed for reimbursement of CyPath® Lung utilizing a combination of CPT codes associated with flow cytometry, including codes 88184,
88185 and 88188. Reimbursement amounts totaled approximately $300 using a combination of the flow cytometry codes that were descriptive
of the test. Based on the existing flow cytometry codes, PPLS’ fee schedule set the price of the test at $905 based on Medicare
reimbursement.
In
June 2023, the AMA issued a CPT code for use in reimbursement of CyPath® Lung, effective October 1, 2023, for private payers and
public health insurance programs, including Medicare and Medicaid. The CPT Proprietary Laboratory Analyses (PLA) code assigned to CyPath®
Lung is 0406U with the descriptor “Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4- carboxyphenyl] porphyrin
[TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer.”
In
July 2023, the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests recommended crosswalking, or using payment for a similar
existing test, to determine the payment for the CPT code specific to CyPath® Lung. In September 2023, CMS released a preliminary
payment decision in line with the Medicare Advisory Panel’s recommendation. The Company then submitted comments during the 30-day
comment period in support of the preliminary decision to crosswalk the payment for CyPath® Lung to CPT code 0021U, which was $760
for the fourth quarter of 2023. Based on that payment, PPLS is currently billing $1,900 for CyPath® Lung. The 2024 Medicare Clinical
Lab Fee Schedule will establish the 2024 Medicare payment for CyPath® Lung and serve as a reference for private payers and other
public health insurance programs. In November 2023, CMS finalized the 2024 payment determination for CPT 0406U, effective January 1,
2024.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
BIOAFFINITY
TECHNOLOGIES, INC. |
|
|
|
By: |
/s/
Maria Zannes |
|
|
Maria Zannes |
|
|
President and Chief Executive
Officer |
|
|
|
Dated: November 30, 2023 |
|
|
Exhibit
99.1
CMS
Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024
SAN
ANTONIO, Texas (Nov. 30, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing
the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the Centers for Medicare
and Medicaid Services (CMS) has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung
cancer, for the 2024 calendar year.
“CyPath®
Lung, our noninvasive test for the detection of early-stage lung cancer, is now on CMS’ 2024 clinical laboratory fee schedule,
a major milestone that facilitates reimbursement by both Medicare and private payers, which in turn should make our test even more attractive
to both physicians and their patients at high risk for lung cancer,” bioAffinity Technologies President and CEO Maria Zannes said.
“The CMS payment determination is an important achievement in our strategic plan to ramp up the commercialization of CyPath®
Lung.”
Based
on the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests recommendation, CMS previously released a preliminary payment
decision for the Current Procedural Terminology (CPT) code specific to CyPath® Lung. For the calendar year 2024 Medicare Clinical
Lab Fee Schedule, CMS finalized the panel’s recommendation for CyPath® Lung for purposes of payment by Medicare. This payment
information also serves as a reference for private payers and other public health insurance programs.
In
June 2023, the American Medical Association (AMA) issued the CPT Proprietary Laboratory Analyses (PLA) code 0406U for CyPath® Lung
with the descriptor “Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4- carboxyphenyl] porphyrin [TCPP], CD206,
CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer.” CMS released a preliminary payment decision in September 2023,
agreeing with the Medicare Advisory Panel’s recommendation. In November 2023, CMS finalized the 2024 payment determination for
CPT 0406U, effective January 1, 2024.
Physicians
can order CyPath® Lung from Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. CyPath®
Lung, a laboratory developed test (LDT), uses flow cytometry to identify cell populations in patient sputum that indicate malignancy.
Automated data analysis developed using proprietary artificial intelligence can help determine if cancer is present or if the patient
is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin, TCPP, that is preferentially taken up by cancer and
cancer-related cells. In a clinical trial, CyPath® Lung showed 92% sensitivity, 87% specificity and 88% accuracy
in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Half of all patients
in the trial who had cancer were diagnosed in early Stages I or II.
The
discovery of small pulmonary nodules as part of annual lung cancer screening using low dose computed tomography (LDCT) can be problematic
to diagnose. Patients may be asked to “wait and see” if the next scan reveals the nodule has grown or proceed immediately
with invasive procedures, including biopsy, that may turn out to be unnecessary. “Actionable results from CyPath® Lung may
help doctors and their patients determine appropriate next steps for suspected cases of lung cancer,” Ms. Zannes said.
About
bioAffinity Technologies, Inc.
bioAffinity
Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer
treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity,
specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed
Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. Research and optimization of
the Company’s platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San
Antonio. For more information, visit www.bioaffinitytech.com and follow us on LinkedIn, Facebook and X.
Forward-Looking
Statements
Certain
statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws.
Words such as “may,” “might,” “will,” “should,” “believe,” “expect,”
“anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,”
“plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are
forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements
regarding CMS’ 2024 clinical laboratory fee schedule making the Company’s test even more attractive to both physicians and
their patients at high risk for lung cancer and CyPath® Lung helping doctors and their patients determine appropriate next steps
for suspected cases of lung cancer. These forward-looking statements are subject to various risks and uncertainties, many of which are
difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth
or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations
include, among others, the ability of the Company to benefit from the 2024 payment determination for CPT 0406U, the ability of the Company’s
test to produce actionable results to help doctors and their patients determine appropriate next steps for suspected cases of lung cancer,
and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and its subsequent
filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts
and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company
believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on
any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does
not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may
be required by applicable securities laws.
Contacts
bioAffinity
Technologies
Julie
Anne Overton
Director
of Communications
jao@bioaffinitytech.com
Investor
Relations
Dave
Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498
BIAF@redchip.com
v3.23.3
Cover
|
Nov. 30, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 30, 2023
|
Entity File Number |
001-41463
|
Entity Registrant Name |
BIOAFFINITY
TECHNOLOGIES, INC.
|
Entity Central Index Key |
0001712762
|
Entity Tax Identification Number |
46-5211056
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
22211
W Interstate 10
|
Entity Address, Address Line Two |
Suite
1206
|
Entity Address, City or Town |
San
Antonio
|
Entity Address, State or Province |
TX
|
Entity Address, Postal Zip Code |
78257
|
City Area Code |
210
|
Local Phone Number |
698-5334
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock, par value $.007 per share |
|
Title of 12(b) Security |
Common
Stock, par value $.007 per share
|
Trading Symbol |
BIAF
|
Security Exchange Name |
NASDAQ
|
Tradeable Warrants to purchase Common Stock |
|
Title of 12(b) Security |
Tradeable
Warrants to purchase Common Stock
|
Trading Symbol |
BIAFW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BIAF_CommonStockParValue.007PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BIAF_TradeableWarrantsToPurchaseCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
bioAffinity Technologies (NASDAQ:BIAF)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
bioAffinity Technologies (NASDAQ:BIAF)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024